The Device Is Only Half the Product: A Quality Manager's View on Coloplast in 2025

In 2025, the medical device is not the product. The system around it is.

I say that as a quality and brand compliance manager at a medical device company. I review every IFU, sterile barrier specification, and customer care script before it reaches clinical teams—roughly 200 items annually. In Q1 2024, I rejected 18% of first deliveries because of documentation gaps. That number used to feel like paperwork. Now it feels like a patient safety signal.

Coloplast is a useful case because its portfolio spans ostomy, continence, wound, and skin care—plus surgical devices. When people search for Coloplast Titan instructions for use, they are not looking for marketing copy. They are looking for the part of the product that tells a clinician or patient how to use it safely. That is the shift I want to talk about. The old view was device first, documentation later. The 2025 view is different. The device, the label, the support line, the sterile package, and the validation method are one system. Miss one part, and the whole product is weaker.

The Old Best Practice Is Not the Current Best Practice

Five years ago, a medtech buyer could evaluate a device mostly on clinical performance, unit price, and maybe a training session. That was reasonable in 2020. It is not enough in 2025. Regulations have tightened. Hospital value analysis committees ask harder questions. Clinical teams are busier. And patients are more informed.

What was best practice in 2020 may not apply in 2025. The fundamentals have not changed—safety, clinical benefit, traceability—but the execution has transformed. The product is no longer just the thing in the box. It is the thing in the box plus the instructions, the customer support, the sterile barrier, and the evidence that all of it works.

When I compared two versions of an IFU side by side—one with a clear warning hierarchy, one with the same text squeezed into smaller type—I finally understood why clinicians call labeling the first safety feature. Same device. Different system. Different risk.

Argument 1: The IFU Is a Safety Feature, Not a Leaflet

Take Coloplast Titan instructions for use. For a high-risk implantable device, the IFU is not a formality. It carries warnings, contraindications, MRI information, device identification, and follow-up guidance. If the revision is wrong, if the translation is ambiguous, if the symbols are not the current ones, the device is not fully compliant. Simple.

In one 2024 audit, we received a batch where the IFU revision did not match the device revision on the label. The vendor called it a minor administrative issue. We rejected the batch. Why? Because a clinician should not have to reconcile paperwork during a procedure. The documentation gap cost the vendor a redo and delayed our launch by three weeks—or rather, closer to five when you count the documentation review.

It is tempting to think this is only a regulatory problem. But the patient experience is also at stake. A patient searching for Coloplast Titan instructions for use may be anxious, fatigued, or reading after surgery. Clear language is not a nice-to-have. It is part of the clinical outcome.

Argument 2: Customer Care Is Quality Data, Not Just a Help Line

Coloplast customer care is often described as support. I would describe it as an early warning system. In 2023, we tracked complaint categories across our own portfolio. A surprising share of packaging complaints—34%—turned out to be IFU confusion: patients could not find the right step, or clinicians misunderstood a storage instruction. The package was fine. The communication was not.

People think customer care follows the product. Actually, customer care often reveals the product. A well-run support team asks structured questions, logs clinical questions, and routes patterns into post-market surveillance and risk management. That is not a cost center. That is quality intelligence.

For B2B buyers, the right question is not whether a supplier has a phone number. It is how that supplier turns calls into corrective actions. Does Coloplast customer care connect to clinical specialists? Are escalations documented? Can procurement see complaint trends? At least, that is the standard I would apply for high-risk categories.

Argument 3: Sterile Barrier Systems and Mechanical Ventilator Workflows Expose the Same Truth

It is tempting to think a sterile barrier system is just a bag. But ISO 11607-1:2019 defines it as more than packaging. It is the minimum system that prevents ingress of microorganisms and allows aseptic presentation. That means materials, seals, sterilization compatibility, shelf life, transport, and storage all have to work together. Under FDA's consensus standards program, ISO 11607-1 and ISO 11607-2 are recognized for terminally sterilized medical devices. The system is the product.

The same logic shows up in critical care. A mechanical ventilator is not a single object. It is a workflow: circuits, filters, humidification, suction, and infection-prevention protocols. CDC surveillance for ventilator-associated events highlights how small process failures can become patient harm. If a sterile barrier fails, if an accessory is mislabeled, if staff improvise because instructions are unclear, the risk climbs.

Even after we approved a new sterile barrier supplier, I kept second-guessing. What if the seal integrity failed in transport? The four weeks until accelerated aging results came back were stressful. In hindsight, I should have pushed for a transport simulation earlier. But with the launch deadline approaching, we made the best call we could with available data.

That is also where what is ELISA becomes relevant. ELISA—enzyme-linked immunosorbent assay—is a plate-based method used to detect and quantify proteins, antibodies, or antigens. In medtech quality control, it can be used in cleaning validation or residue testing to see whether a surface or material is actually clean. It is not a device. It is a verification method. And verification methods are part of the product system because they turn claims into evidence.

The Counterargument: Is This Just Bureaucracy?

A reasonable person might say: all this labeling, support, and validation slows innovation. Clinicians care about outcomes, not paperwork. I agree with the frustration. But the causality runs the other way. People think documentation causes delays. Actually, missing documentation causes delays. In 2022, a documentation gap cost us a $22,000 redo and delayed a launch. The device itself was fine. We just could not prove it was fine.

I am not arguing for more paperwork for its own sake. Traditional paper IFUs still work in many markets. In-person training still matters. Some legacy processes are reliable. The point is not to discard the old. The point is to update the old with clearer revision control, better translation, structured customer care, and validated packaging. The fundamentals stay. The execution moves forward.

What I Would Ask Coloplast—and Any Medtech Supplier—in 2025

If you are evaluating a supplier for a B2B healthcare setting, do not stop at the device brochure. Ask for the system:

• Can you show revision control for Coloplast Titan instructions for use across markets and languages?
• How does Coloplast customer care route clinical questions into post-market surveillance?
• Are your sterile barrier system validations aligned with ISO 11607-1 and -2, including transport and aging?
• For mechanical ventilator accessories, how do you separate cleaning claims from sterilization claims?
• If you use ELISA in QC, what are your controls, limits of detection, and validation data?

Those questions sound technical. They are. But they are also commercial. A supplier that cannot answer them is not selling a complete product. It is selling a device with missing pieces.

The Viewpoint, Restated

The industry has evolved. In 2020, the device was often enough. In 2025, the product is the device plus its instructions, customer care, sterile barrier, and verification methods. Coloplast is one example—not the only one—of a company operating in that reality. The fundamentals have not changed: safety, clinical benefit, and traceability. But the execution has transformed.

So when you evaluate Coloplast or any medtech supplier, do not ask only what the device does. Ask what surrounds it. Because that system is what reaches the patient. That is the product. Done.